Trial reportAJNR. American journal of neuroradiology2010
Percutaneous vertebroplasty is not a risk factor for new osteoporotic compression fractures: results from VERTOS II.
Trial report in AJNR. American journal of neuroradiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 8 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- ESR Essentials: percutaneous bone consolidation-practice recommendations by the European Society of Musculoskeletal Radiology.European radiology · 2025Guideline
- Incidence of new osteoporotic adjacent vertebral body fractures. A comparison between conservative treatment and vertebral body augmentation (vertebroplasty, kyphoplasty): a systematic review and meta-analysis.Frontiers in surgery · 2025Pooled it
- "How to measure the outcome in the surgical treatment of vertebral compression fractures? A systematic literature review of highly cited level-I studies".BMC musculoskeletal disorders · 2021Pooled it
- Clinical and radiological subsequent fractures after vertebral augmentation for treating osteoporotic vertebral compression fractures: a meta-analysis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2020Pooled it
- Percutaneous vertebroplasty for osteoporotic vertebral compression fracture.The Cochrane database of systematic reviews · 2018Pooled it
- Percutaneous vertebroplasty for osteoporotic vertebral compression fracture.The Cochrane database of systematic reviews · 2018Pooled it
- The Incidence of New Vertebral Fractures Following Vertebral Augmentation: A Meta-Analysis of Randomized Controlled Trials.Medicine · 2015Pooled it
- Surgical versus non-surgical treatment for vertebral compression fracture with osteopenia: a systematic review and meta-analysis.PloS one · 2015Pooled it
- Prophylactic Percutaneous Kyphoplasty Treatment for Nonfractured Vertebral Bodies in Thoracolumbar for Osteoporotic Patients.BioMed research international · 2020Trial
- New vertebral fractures after vertebroplasty: 2-year results from a randomised controlled trial.Archives of osteoporosis · 2015Trial
- Recompression in new levels after percutaneous vertebroplasty and kyphoplasty compared with conservative treatment.Archives of orthopaedic and trauma surgery · 2014Trial
- Factors Affecting Recollapse of the Augmented Vertebrae After Percutaneous Vertebral Augmentation: A Prospective Study.Aging medicine (Milton (N.S.W)) · 2026Article
- Article
- Analysis of Risk Factors for Augmented Vertebral Refracture After Percutaneous Kyphoplasty in Osteoporotic Vertebral Compression Fractures.Journal of clinical medicine · 2025Article
- Percutaneous Vertebroplasty and Balloon Kyphoplasty for Painful Osteoporotic Vertebral Compression Fractures: A Health Technology Assessment.Ontario health technology assessment series · 2025Article
- Machine learning-driven prediction of risk factors for postoperative re-fractures in elderly OVCF patients with underlying diseases: model development and validation.Frontiers in medicine · 2025Article
- Clinical and radiographical analysis of percutaneous kyphoplasty with multi-point cement anchoring technique for preventing bone cement displacement in Kümmell's disease of stage I and II.Frontiers in endocrinology · 2025Article
- Risk of new vertebral compression fractures and serious adverse effects after vertebroplasty: a systematic, critical review and meta-analysis of randomized controlled trials.Quantitative imaging in medicine and surgery · 2024Article
- Factors influencing further vertebral height loss following percutaneous vertebroplasty in osteoporotic vertebral compression fractures: A 1-year follow-up study.World journal of clinical cases · 2024Article
- Predicting osteoporotic fractures post-vertebroplasty: a machine learning approach with a web-based calculator.BMC surgery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposePV is increasingly used as treatment for osteoporotic VCFs. However, controversy exists as to whether PV increases the risk for new VCFs during follow-up. The purpose of our research was to assess the incidence of new VCFs in patients with acute VCFs randomized to PV and conservative therapy. MATERIALS AND
methodsVERTOS II is a prospective multicenter randomized controlled trial comparing PV with conservative therapy in 202 patients. Incidence, distribution, and timing of new VCFs during follow-up were assessed from spine radiographs. In addition, further height loss during follow-up of treated VCFs was measured.
resultsAfter a mean follow-up of 11.4 months (median, 12.0; range, 1-24 months), 18 new VCFs occurred in 15 of 91 patients after PV and 30 new VCFs in 21 of 85 patients after conservative therapy. This difference was not significant (P = .44). There was no higher fracture risk for adjacent-versus-distant vertebrae. Mean time to new VCF was 16.2 months after PV and 17.8 months after conservative treatment (logrank, P = .45). The baseline number of VCFs was the only risk factor for occurrence (OR, 1.43; 95% CI, 1.05-1.95) and number (P = .01) of new VCFs. After conservative therapy, further height loss of treated vertebrae occurred more frequently (35 of 85 versus 11 of 91 patients, P < .001) and was more severe (P < .001) than after PV.
conclusionsIncidence of new VCFs was not different after PV compared with conservative therapy after a mean of 11.4 months' follow-up. The only risk factor for new VCFs was the number of VCFs at baseline. PV contributed to preservation of stature by decreasing both the incidence and severity of further height loss in treated vertebrae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.